<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>15</Volume>
				<Issue>20</Issue>
				<PubDate PubStatus="epublish">
					<Year>2014</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Association between the TGFBR2 G-875A Polymorphism and Cancer Risk: Evidence from a Meta-analysis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>8705</FirstPage>
			<LastPage>8708</LastPage>
			<ELocationID EIdType="pii">29982</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Disrupted transforming growth factor- β (TGF-β) signaling is involved in the development of various types ofcancer and the TGF-β receptor II (TGFBR2) is a key mediator of TGF-β growth inhibitory signals. It is reportedthat the G-875A polymorphism in TGFBR2 is implicated in risk of various cancers. However, results for theassociation between this polymorphism and cancer remain conflicting. To derive a more precise estimation, ameta-analysis of 3,808 cases and 4,489 controls from nine published case-control studies was performed. Ouranalysis indicated that G-875A is associated with a trend of decreased cancer risk for allele A versus(vs.) alleleG [odds ratio (OR) =0.64, 95% confidence intervals (CI): 0.55-0.74], as well as for both dominant model [(A/A+G/A) vs. G/G, OR=0.76, 95% CI: 0.64-0.90] and recessive model [A/A vs. (G/G+G/A), OR=0.74, 95% CI:0.59-0.93). However, larger scale primary studies are required to further evaluate the interaction of TGFBR2G-875A polymorphism and cancer risk in specific cancer subtypes.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">TGFBR2</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Polymorphism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cancer risk</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Meta-analysis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_29982_03f6ae0d931074e13c568d137628c3c2.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
